The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Mechanistic Biomarkers Provide Early and Sensitive Detection of Acetaminophen-Induced Acute Liver Injury at First Presentation to Hospital
Open accessAbstract
Acetaminophen overdose is a common reason for hospital admission and the most frequent cause of hepatotoxicity in the Western world. Early identification would facilitate patient-individualized treatment strategies. We investigated the potential of a panel of novel biomarkers (with enhanced liver expression or linked to the mechanisms of toxicity) to identify patients with acetaminophen-induced acute liver injury (ALI) at first presentation to the hospital when currently used markers are within the normal range. In the first hospital presentation plasma sample from patients (n = 129), we measured microRNA-122 (miR-122; high liver specificity), high mobility group box-1 (HMGB1; marker of necrosis), full-length and caspase-cleaved keratin-18 (K18; markers of necrosis and apoptosis), and glutamate dehydrogenase (GLDH; marker of mitochondrial dysfunction). Receiver operator characteristic curve analysis and positive/negative predictive values were used to compare sensitivity to report liver injury versus alanine transaminase (ALT) and International Normalized Ratio (INR). In all patients, biomarkers at first presentation significantly correlated with peak ALT or INR. In patients presenting with normal ALT or INR, miR-122, HMGB1, and necrosis K18 identified the development of liver injury (n = 15) or not (n = 84) with a high degree of accuracy and significantly outperformed ALT, INR, and plasma acetaminophen concentration for the prediction of subsequent ALI (n = 11) compared with no ALI (n = 52) in patients presenting within 8 hours of overdose. Conclusion : Elevations in plasma miR-122, HMGB1, and necrosis K18 identified subsequent ALI development in patients on admission to the hospital, soon after acetaminophen overdose, and in patients with ALTs in the normal range. The application of such a biomarker panel could improve the speed of clinical decision-making, both in the treatment of ALI and the design/execution of patient-individualized treatment strategies. (Hepatology 2013;58:777–787)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, glutamate dehydrogenase and micro‐RNA‐122 show promise as being more sensitive and specific biomarkers for liver injury compared with ALT from clinical studies in patients with APAP overdose (Table 12).210,211”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Antoine, D. J., Jenkins, R. E., Dear, J. W., Williams, D. P., McGill, M. R., Sharpe, M. R., Craig, D. G., Simpson, K. J., Jaeschke, H., & Park, B. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.019 · Cited by 309
Self-citationRetractedMechanistic biomarkers in acute liver injury: Are we there yet?
Adebayo, D., Mookerjee, R. P., & Jalan, R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.017 · Cited by 21
RetractedMonocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion
Bonaldi, T. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg516 · Cited by 1,249
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Bernal, W., Auzinger, G., Dhawan, A., & Wendon, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60274-7 · Cited by 996
Jaeschke, H., McGill, M. R., & Ramachandran, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.602688 · Cited by 964
Characterization of microRNA expression profiles in normal human tissues.
Liang, Y., Ridzon, D., Wong, L., & Chen, C. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-166 · Cited by 881
McGill, M. R., Sharpe, M. R., Williams, C. D., Taha, M., Curry, S. C., & Jaeschke, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59755 · Cited by 763
Circulating microRNAs as potential markers of human drug-induced liver injury
Starkey Lewis, P. J., Dear, J., Platt, V., Simpson, K. J., Craig, D. G. N., Antoine, D. J., French, N. S., Dhaun, N., Webb, D. J., Costello, E. M., et al. (2011) · Hepatology · doi:10.1002/hep.24538 · Cited by 515
Self-citationAntoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., & Park, B. K. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp235 · Cited by 223
Self-citation
Cited by
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
The past and present of serum aminotransferases and the future of liver injury biomarkers
McGill, M. R. (2016) · EXCLI journal · doi:10.17179/excli2016-800 · Cited by 487
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
MD-2 is required for disulfide HMGB1–dependent TLR4 signaling
Yang, H., Wang, H., Ju, Z., Ragab, A. A., Lundbäck, P., Long, W., Valdes-Ferrer, S. I., He, M., Pribis, J. P., Li, J., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141318 · Cited by 375
Self-citationThe HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Huebener, P., Pradere, J.-P., Hernandez, C., Gwak, G.-Y., Caviglia, J. M., Mu, X., Loike, J. D., Jenkins, R. E., Antoine, D. J., & Schwabe, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76887 · Cited by 354
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Ramachandran, A., & Jaeschke, H. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679919 · Cited by 326
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Huebener, P., Pradere, J.-P., Hernandez, C., Gwak, G.-Y., Caviglia, J. M., Mu, X., Loike, J. D., Jenkins, R. E., Antoine, D. J., & Schwabe, R. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126975 · Cited by 300
Self-citationExtracellular vesicles: mediators of intercellular communication in tissue injury and disease
Berumen Sánchez, G., Bunn, K. E., Pua, H. H., & Rafat, M. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00787-y · Cited by 289
Extracellular HMGB1 as a therapeutic target in inflammatory diseases
Andersson, U., Yang, H., & Harris, H. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1439924 · Cited by 287
The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure
Triantafyllou, E., Woollard, K. J., McPhail, M. J. W., Antoniades, C. G., & Possamai, L. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02948 · Cited by 285
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9793-2 · Cited by 254
Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
Mihm, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103104 · Cited by 232
Church, R. J., Kullak‐Ublick, G. A., Aubrecht, J., Bonkovsky, H. L., Chalasani, N., Fontana, R. J., Goepfert, J. C., Hackman, F., King, N. M. P., Kirby, S., et al. (2019) · Hepatology · doi:10.1002/hep.29802 · Cited by 231
Chidiac, A. S., Buckley, N. A., Noghrehchi, F., & Cairns, R. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2223959 · Cited by 215
McGill, M. R., Staggs, V. S., Sharpe, M. R., Lee, W. M., & Jaeschke, H. (2014) · Hepatology · doi:10.1002/hep.27265 · Cited by 148
Bateman, D. N., Carroll, R., Pettie, J., Yamamoto, T., Elamin, M. E. M. O., Peart, L., Dow, M., Coyle, J., Cranfield, K. R., Hook, C., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12362 · Cited by 131
Self-citationModels of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
Dear, J. W., Clarke, J. I., Francis, B., Allen, L., Wraight, J., Shen, J., Dargan, P. I., Wood, D., Cooper, J., Thomas, S. H. L., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30266-2 · Cited by 123
Self-citationChiew, A. L., Isbister, G. K., Kirby, K. A., Page, C. B., Chan, B. S. H., & Buckley, N. A. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1334915 · Cited by 107
Stine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
Krauskopf, J., Caiment, F., Claessen, S. M., Johnson, K. J., Warner, R. L., Schomaker, S. J., Burt, D. A., Aubrecht, J., & Kleinjans, J. C. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu232 · Cited by 93
Risk prediction of hepatotoxicity in paracetamol poisoning
Wong, A., & Graudins, A. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1317349 · Cited by 88
Drug-induced liver injury: Highlights from a review of the 2015 literature
Sarges, P., Steinberg, J. M., & Lewis, J. H. (2016) · Drug Safety · doi:10.1007/s40264-016-0427-8 · Cited by 74
Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5)
Chiew, A. L., James, L. P., Isbister, G. K., Pickering, J. W., McArdle, K., Chan, B. S. H., & Buckley, N. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.030 · Cited by 53
Acetylcysteine in paracetamol poisoning: a perspective of 45 years of use
Bateman, D. N., & Dear, J. W. (2019) · Toxicology Research · doi:10.1039/c9tx00002j · Cited by 53
Self-citationThe Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
Moreno-Torres, M., Quintás, G., & Castell, J. V. (2022) · Metabolites · doi:10.3390/metabo12060564 · Cited by 50
Morrison, E. E., Oatey, K., Gallagher, B., Grahamslaw, J., O'Brien, R., Black, P., Oosthuyzen, W., Lee, R. J., Weir, C. J., Henriksen, D., et al. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.07.013 · Cited by 48
Self-citationClarke, J. I., Dear, J. W., & Antoine, D. J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1160057 · Cited by 46
Self-citationGene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis
Ippolito, D. L., AbdulHameed, M. D. M., Tawa, G. J., Baer, C. E., Permenter, M. G., McDyre, B. C., Dennis, W. E., Boyle, M. H., Hobbs, C. A., Streicker, M. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv214 · Cited by 43
Dear, J. W., & Antoine, D. J. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.880650 · Cited by 34
Self-citationCirculating acetaminophen metabolites are toxicokinetic biomarkers of acute liver injury
Vliegenthart, A., Kimmitt, R., Seymour, J., Homer, N., Clarke, J., Eddleston, M., Gray, A., Wood, D., Dargan, P., Cooper, J., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.541 · Cited by 31
Self-citationModified release paracetamol overdose: a prospective observational study (ATOM-3)
Chiew, A. L., Isbister, G. K., Page, C. B., Kirby, K. A., Chan, B. S. H., & Buckley, N. A. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1439950 · Cited by 30
Serum biomarkers of drug‐induced liver injury: Current status and future directions
Church, R. J., & Watkins, P. B. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12684 · Cited by 27
Cueto‐Sánchez, A., Niu, H., Álvarez‐Álvarez, I., López‐Longarela, B., Del Campo‐Herrera, E., Ortega‐Alonso, A., García‐Cortés, M., Pinazo‐Bandera, J., Sanabria‐Cabrera, J., Díaz‐Mochón, J. J., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15724 · Cited by 24
Iruzubieta, P., Arias-Loste, M. T., Barbier-Torres, L., Martinez-Chantar, M. L., & Crespo, J. (2015) · BioMed Research International · doi:10.1155/2015/386186 · Cited by 24
Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity
Gloor, Y., Schvartz, D., & F.Samer, C. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1642323 · Cited by 18
Liu, Y., Zhan, S.-P., Song, L., Chen, Y., Jia, Y.-T., Liu, F., Sun, F.-J., Wang, Q., & Xia, P.-Y. (2020) · Medical Science Monitor · doi:10.12659/msm.919435 · Cited by 6
Metadata
- Authors
- Antoine, D. J., Dear, J. W., Lewis, P. S., Platt, V., Coyle, J., Masson, M., Thanacoody, R. H., Gray, A. J., Webb, D. J., Moggs, J. G., Bateman, N. D., Goldring, C. E., & Park, K. B.
- Venue
- Hepatology
- Published
- 2013-08
- Volume
- 58
- Issue
- 2
- Pages
- 777-787
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2093982770
- Cited by
- 427
- References
- 21
- FWCI
- 51.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.